Cite
HARVARD Citation
Singh, J. et al. (2017). Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist. pp. 139-143. [Online].